These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29084917)

  • 1. Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.
    Morrow MP; Kraynyak KA; Sylvester AJ; Dallas M; Knoblock D; Boyer JD; Yan J; Vang R; Khan AS; Humeau L; Sardesai NY; Kim JJ; Plotkin S; Weiner DB; Trimble CL; Bagarazzi ML
    Clin Cancer Res; 2018 Jan; 24(2):276-294. PubMed ID: 29084917
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.
    Bagarazzi ML; Yan J; Morrow MP; Shen X; Parker RL; Lee JC; Giffear M; Pankhong P; Khan AS; Broderick KE; Knott C; Lin F; Boyer JD; Draghia-Akli R; White CJ; Kim JJ; Weiner DB; Sardesai NY
    Sci Transl Med; 2012 Oct; 4(155):155ra138. PubMed ID: 23052295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
    Bhuyan PK; Dallas M; Kraynyak K; Herring T; Morrow M; Boyer J; Duff S; Kim J; Weiner DB
    Hum Vaccin Immunother; 2021 May; 17(5):1288-1293. PubMed ID: 33175656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial.
    Van Damme P; Bouillette-Marussig M; Hens A; De Coster I; Depuydt C; Goubier A; Van Tendeloo V; Cools N; Goossens H; Hercend T; Timmerman B; Bissery MC
    Clin Cancer Res; 2016 Jul; 22(13):3238-48. PubMed ID: 27252412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Alvarez RD; Huh WK; Bae S; Lamb LS; Conner MG; Boyer J; Wang C; Hung CF; Sauter E; Paradis M; Adams EA; Hester S; Jackson BE; Wu TC; Trimble CL
    Gynecol Oncol; 2016 Feb; 140(2):245-52. PubMed ID: 26616223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
    van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
    Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model.
    Ma Y; Yang A; Peng S; Qiu J; Farmer E; Hung CF; Wu TC
    Vaccine; 2017 Jul; 35(31):3850-3858. PubMed ID: 28599791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica.
    Coseo S; Porras C; Hildesheim A; Rodriguez AC; Schiffman M; Herrero R; Wacholder S; Gonzalez P; Wang SS; Sherman ME; Jimenez S; Solomon D; Bougelet C; van Doorn LJ; Quint W; Safaeian M;
    Sex Transm Dis; 2010 Nov; 37(11):706-14. PubMed ID: 20661178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.
    Maldonado L; Teague JE; Morrow MP; Jotova I; Wu TC; Wang C; Desmarais C; Boyer JD; Tycko B; Robins HS; Clark RA; Trimble CL
    Sci Transl Med; 2014 Jan; 6(221):221ra13. PubMed ID: 24477000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.
    Jiang RT; Wang JW; Peng S; Huang TC; Wang C; Cannella F; Chang YN; Viscidi RP; Best SRA; Hung CF; Roden RBS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28515303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract.
    Vinokurova S; Wentzensen N; Einenkel J; Klaes R; Ziegert C; Melsheimer P; Sartor H; Horn LC; Höckel M; von Knebel Doeberitz M
    J Natl Cancer Inst; 2005 Dec; 97(24):1816-21. PubMed ID: 16368943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of human papillomavirus types and phylogenetic analysis of HPV-16 L1 variants from Southern India.
    Kabekkodu SP; Bhat S; Pandey D; Varghese VK; Shukla V; Ghosh S; Kushtagi P; Bhat P; Gopinath PM; Satyamoorthy K
    Asian Pac J Cancer Prev; 2015; 16(5):2073-80. PubMed ID: 25773853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO; Cariri FA; Aps LR; Ferreira LC
    Hum Gene Ther; 2013 Oct; 24(10):861-70. PubMed ID: 24007495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic DNA Vaccine Against HPV16-Associated Cancer.
    Yu M; Chandra J
    Methods Mol Biol; 2021; 2197():241-252. PubMed ID: 32827141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element.
    Piersma SJ; Welters MJ; van der Hulst JM; Kloth JN; Kwappenberg KM; Trimbos BJ; Melief CJ; Hellebrekers BW; Fleuren GJ; Kenter GG; Offringa R; van der Burg SH
    Int J Cancer; 2008 Feb; 122(3):486-94. PubMed ID: 17955486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia.
    Molling JW; de Gruijl TD; Glim J; Moreno M; Rozendaal L; Meijer CJ; van den Eertwegh AJ; Scheper RJ; von Blomberg ME; Bontkes HJ
    Int J Cancer; 2007 Oct; 121(8):1749-55. PubMed ID: 17582606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India.
    Berlin Grace VM
    Indian J Cancer; 2009; 46(3):203-7. PubMed ID: 19574671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.